Sandridge Energy Inc.(SD),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community

At the request of the exchanges, the U.S./Hong Kong stock quotes are displayed on a 15-minute delay, download the APP to view the real-time quotes for free.

Close

SD Sandridge Energy Inc.

Trading 05-10 10:05:15 EDT

13.42

-0.16

-1.18%

High13.66	Low13.39	Vol19.39K
Open13.66	D1 Closing13.58	Amplitude1.99%
Mkt Cap497.50M	Tradable Cap491.40M	Total Shares37.07M
T/O261.53K	T/O Rate0.05%	Tradable Shares36.62M
P/B--	ROE--	EPS0.00
52wk High--	52wk Low--	P/E--
Dividend--	Div.Yield--	ROA--

{"stockData":{"symbol":"SD","market":"US","secType":"STK","nameCN":"Sandridge Energy Inc.","latestPrice":13.4199,"timestamp":1715349906765,"preClose":13.58,"halted":0,"volume":19394,"delay":0,"floatShares":36617302,"shares":37071450,"eps":1.300203,"marketStatus":"Trading","change":-0.1601,"latestTime":"05-10 10:05:15 EDT","open":13.66,"high":13.66,"low":13.3901,"amount":261534.548202,"amplitude":0.019875,"askPrice":13.42,"askSize":145,"bidPrice":13.41,"bidSize":112,"shortable":3,"etf":0,"ttmEps":1.300203,"tradingStatus":2,"nextMarketStatus":{"tag":"Post-Market Trading","tradingStatus":3,"beginTime":1715371200000},"marketStatusCode":2,"adr":0,"adrRate":0,"listingDate":1475553600000,"exchange":"NYSE","adjPreClose":13.58,"dividendRate":0.014903,"postHourTrading":{"tag":"盘后","latestPrice":13.58,"preClose":13.58,"latestTime":"19:59 EDT","volume":75391,"amount":1023811.9,"timestamp":1715299163848},"volumeRatio":0.67026},"requestUrl":"/m/hq/s/SD/wiki","defaultTab":"wiki","newsList":[{"id":"2434834211","title":"SandRidge Energy First Quarter 2024 Earnings: EPS: US$0.30 (vs US$0.65 in 1Q 2023)","url":"https://stock-news.laohu8.com/highlight/detail?id=2434834211","media":"Simply Wall St.","top":-1,"share":"https://ttm.financial/m/news/2434834211?lang=en_us&edition=fundamental","pubTime":"2024-05-10 18:49","pubTimestamp":1715338149,"startTime":"0","endTime":"0","summary":"Profit margin: 37% . The decrease in margin was driven by lower revenue.NYSE:SD Earnings and Revenue History May 10th 2024. All figures shown in the chart above are for the trailing 12 month  period. SandRidge Energy's share price is broadly unchanged from a week ago.We should say that we've discovered 2 warning signs for SandRidge Energy that you should be aware of before investing here.","market":"us","thumbnail":"https://s.yimg.com/uu/api/res/1.2/5Vpve0Pc2F3m_L3fs2p_dQ--~B/aD02MzY7dz05NDU7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/simply_wall_st__316/78a8c60a6283aea0450523395306d38c","type":0,"news_type":0,"thumbnails":["https://s.yimg.com/uu/api/res/1.2/5Vpve0Pc2F3m_L3fs2p_dQ--~B/aD02MzY7dz05NDU7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/simply_wall_st__316/78a8c60a6283aea0450523395306d38c"],"rights":null,"property":["earning"],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/sandridge-energy-first-quarter-2024-104909104.html","is_publish_highlight":false,"gpt_icon":0},{"id":"2434523110","title":"SandRidge Energy Inc (SDRPQ.PFD) (Q1 2024) Earnings Call Transcript Highlights: Robust ...","url":"https://stock-news.laohu8.com/highlight/detail?id=2434523110","media":"GuruFocus.com","top":-1,"share":"https://ttm.financial/m/news/2434523110?lang=en_us&edition=fundamental","pubTime":"2024-05-09 15:31","pubTimestamp":1715239907,"startTime":"0","endTime":"0","summary":"Interest Income: $2.7 million from high yield deposit accounts. Dividends: Total cumulative dividends of $141 million or $3.81 per share; Q1 2024 dividend of $0.11 per share, a 10% increase from 2023. Cash Position: Over $208 million, equating to more than $5.60 per share. Long-term Debt: None reported as of March 31, 2024. Commodity Price Realizations: $75.8 per barrel of oil, $1.25 per Mcf of gas, $23.65 per barrel of NGLs. Net Operating Loss : Estimated at $1.6 billion. GuruFocus has detected 3 Warning Sign with SDRPQ.PFD.For the complete transcript of the earnings call, please refer to the full earnings call transcript.SandRidge Energy Inc  reported generating adjusted EBITDA of nearly $15 million, reflecting strong operational performance despite natural gas price fluctuations.SandRidge Energy Inc  successfully converted over 99% of its EBITDA to free cash flow, indicating highly effective capital management and operational efficiency.Q: Can you provide an overview of SandRidge En","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["earning"],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/sandridge-energy-inc-sdrpq-pfd-073147332.html","is_publish_highlight":false,"gpt_icon":0},{"id":"2434373110","title":"Q1 2024 SandRidge Energy Inc Earnings Call","url":"https://stock-news.laohu8.com/highlight/detail?id=2434373110","media":"Thomson Reuters StreetEvents","top":-1,"share":"https://ttm.financial/m/news/2434373110?lang=en_us&edition=fundamental","pubTime":"2024-05-09 12:44","pubTimestamp":1715229852,"startTime":"0","endTime":"0","summary":"Scott Prestridge; SVP - Finance Strategies; SandRidge Energy Inc. Grayson Pranin; President & CEO; SandRidge Energy Inc. Dean Parrish; Chief Operating Officer, Senior Vice President; SandRidge Energy Inc. Ladies and gentlemen, thank you for standing by, and welcome to the First Quarter 2024 SandRidge Energy conference call.  As a reminder, today's call is being recorded. I will now hand today's call over to Scott Prestridge, SVP of Finance Strategies. Please go ahead, sir.Thank you and good morning. I'm pleased to report on another quarter that the company's activity continues to translate to free cash flow from our producing assets. Before expanding on this, Brandon will touch on a few highlights.","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["earning"],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/q1-2024-sandridge-energy-inc-044412535.html","is_publish_highlight":false,"gpt_icon":0},{"id":"2433740028","title":"Aptevo Therapeutics Reports 1Q 2024 Financial Results and Provides a Business Update","url":"https://stock-news.laohu8.com/highlight/detail?id=2433740028","media":"ACCESSWIRE","top":-1,"share":"https://ttm.financial/m/news/2433740028?lang=en_us&edition=fundamental","pubTime":"2024-05-08 20:05","pubTimestamp":1715169900,"startTime":"0","endTime":"0","summary":"Heavily pre-treated breast cancer patient who achieved stable disease on study, remains on treatment for more than eleven months after entering the ALG.APV-527 Phase 1 trial with progressive disease and transitioning to higher dose with potential for greater clinical benefit, experienced no new adverse events since the transition to the higher dose level. \"Aptevo has had an exciting first quarter, making progress in both clinical programs. We are particularly enthusiastic about one breast cancer patient in our ALG.APV-527 trial who has remained on study with stable disease for more than eleven months, in addition, to being safely and successfully transitioned to a higher dose level within the study. This rarely happens in an early-stage trial, and we believe it underscores the potential of our bispecific solid tumor candidate,\" said Marvin White, President & CEO of Aptevo. \"Additionally, we plan to initiate our APVO436 dose optimization trial in frontline AML patients this quarter. Ove","market":"us","thumbnail":"https://s.yimg.com/uu/api/res/1.2/KX4lFghIfeHvaf3GE2OfYQ--~B/aD00MDA7dz00MDA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/accesswire.ca/5c87d755d6d224cdf4b775531ab18087","type":0,"news_type":0,"thumbnails":["https://s.yimg.com/uu/api/res/1.2/KX4lFghIfeHvaf3GE2OfYQ--~B/aD00MDA7dz00MDA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/accesswire.ca/5c87d755d6d224cdf4b775531ab18087"],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/aptevo-therapeutics-reports-1q-2024-120500981.html","is_publish_highlight":false,"gpt_icon":0},{"id":"2433874292","title":"Acepodia Announces Preliminary Clinical Data From Phase 1 Clinical Trial of ACE1831, First-Ever Anti-CD20 Antibody Conjugated Allogenic Gamma Delta T Cell Therapy for Non-Hodgkins Lymphoma","url":"https://stock-news.laohu8.com/highlight/detail?id=2433874292","media":"PR Newswire","top":-1,"share":"https://ttm.financial/m/news/2433874292?lang=en_us&edition=fundamental","pubTime":"2024-05-08 19:00","pubTimestamp":1715166000,"startTime":"0","endTime":"0","summary":"First dosingdohort was completed with complete response and disease stabilization identified at three months at the lowest dose level in the Phase 1 study. No ACE1831-related serious adverse events, includingGvHD, neurotoxicity, high-grade CRS or dose limiting toxicities were observed. ALAMEDA, Calif. and TAIPEI, May 8, 2024 /PRNewswire/ -- Acepodia , a clinical stage biotechnology company developing first-in-class cell therapies with its unique Antibody-Cell Conjugation  and allogeneic gamma delta 2 (γδ2)T cell platforms to address gaps in cancer care, today announced preliminary data from its Phase 1 dose escalation clinical trial of ACE1831, an anti-CD20 antibody conjugated allogeneic gamma delta T cell therapy being evaluated in patients with non-Hodgkin's lymphoma .\"This ongoing trial is the first to demonstrate potential clinical benefit to patients using biorthogonal chemistry and opens the door to a powerful, new approach for cell therapy that overcomes limitations of current C","market":"us","thumbnail":"https://s.yimg.com/uu/api/res/1.2/Y.qMulLzkNn28gFBy.3ICw--~B/aD0xNjt3PTE2O2FwcGlkPXl0YWNoeW9u/https://media.zenfs.com/en/prnewswire.com/c3f81a0afc9e1374519be281870519c1","type":0,"news_type":0,"thumbnails":["https://s.yimg.com/uu/api/res/1.2/Y.qMulLzkNn28gFBy.3ICw--~B/aD0xNjt3PTE2O2FwcGlkPXl0YWNoeW9u/https://media.zenfs.com/en/prnewswire.com/c3f81a0afc9e1374519be281870519c1"],"rights":{"source":"yahoofinance","url":"https://finance.yahoo.com/news/acepodia-announces-preliminary-clinical-data-110000137.html","rn_cache_url":null,"customStyle":"img, svg { display: none !important; }","selectors":"article","filters":"","directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/acepodia-announces-preliminary-clinical-data-110000137.html","is_publish_highlight":false,"gpt_icon":0},{"id":"2433768160","title":"SandRidge Energy Inc. Reports Q1 2024 Earnings: Steady Income Amidst Operational Adjustments","url":"https://stock-news.laohu8.com/highlight/detail?id=2433768160","media":"GuruFocus.com","top":-1,"share":"https://ttm.financial/m/news/2433768160?lang=en_us&edition=fundamental","pubTime":"2024-05-08 09:03","pubTimestamp":1715130228,"startTime":"0","endTime":"0","summary":"Net Income: $11.1 million for Q1 2024, with earnings per share at $0.30.Adjusted EBITDA: Reported at $14.7 million for the first quarter of 2024.Free Cash Flow: Generated $14.5 million in Q1 2024, representing a 99% conversion rate relative to adjusted EBITDA.Cash Dividend: Declared a $0.11 per share cash dividend payable on May 31, 2024.Revenue: Total revenue of $30.3 million for the quarter, with oil contributing 51%.SandRidge Energy Inc  disclosed its financial and operational results for the first quarter ended March 31, 2024, through its 8-K filing on May 7, 2024. The U.S.-based oil and natural gas company, which focuses on the exploration, development, and production of crude oil, natural gas, and natural gas liquids, particularly in the Mid-Continent region of Oklahoma and Kansas, has declared a $0.11 per share cash dividend amidst a period of strategic operational enhancements.SandRidge continues to prioritize high-return projects and capital discipline, adapting to the fluctua","market":"us","thumbnail":"https://s.yimg.com/uu/api/res/1.2/1P8l6BEh78P2O1QWurrbzA--~B/aD01NTc7dz0xMjQyO2FwcGlkPXl0YWNoeW9u/https://media.zenfs.com/en/us.finance.gurufocus/898981e79906df1d2193f59e76e035be","type":0,"news_type":0,"thumbnails":["https://s.yimg.com/uu/api/res/1.2/1P8l6BEh78P2O1QWurrbzA--~B/aD01NTc7dz0xMjQyO2FwcGlkPXl0YWNoeW9u/https://media.zenfs.com/en/us.finance.gurufocus/898981e79906df1d2193f59e76e035be"],"rights":null,"property":["earning"],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/sandridge-energy-inc-reports-q1-010348338.html","is_publish_highlight":false,"gpt_icon":0},{"id":"2433535207","title":"SandRidge Energy Q1 Adj $0.30 Down From $0.64 YoY, Sales $30.28M Down From $43.15M YoY","url":"https://stock-news.laohu8.com/highlight/detail?id=2433535207","media":"Benzinga","top":-1,"share":"https://ttm.financial/m/news/2433535207?lang=en_us&edition=fundamental","pubTime":"2024-05-08 05:32","pubTimestamp":1715117573,"startTime":"0","endTime":"0","summary":"SandRidge Energy (NYSE:SD) reported quarterly earnings of $0.30 per share. This is a 53.13 percent decrease over earnings of $0.64 per share from the same period last year.  The company reported $30.28 million in sales","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["earning"],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://www.benzinga.com/news/earnings/24/05/38686115/sandridge-energy-q1-adj-0-30-down-from-0-64-yoy-sales-30-28m-down-from-43-15m-yoy","is_publish_highlight":false,"gpt_icon":0},{"id":"2433116730","title":"SANDRIDGE ENERGY, INC. ANNOUNCES FINANCIAL AND OPERATING RESULTS FOR THE THREE-MONTH PERIOD ENDED MARCH 31, 2024 AND DECLARES $0.11 PER SHARE CASH DIVIDEND","url":"https://stock-news.laohu8.com/highlight/detail?id=2433116730","media":"PR Newswire","top":-1,"share":"https://ttm.financial/m/news/2433116730?lang=en_us&edition=fundamental","pubTime":"2024-05-08 04:16","pubTimestamp":1715112960,"startTime":"0","endTime":"0","summary":"OKLAHOMA CITY, Okla., May 7, 2024 /PRNewswire/ -- SandRidge Energy, Inc.   today announced financial and operational results for the three-month period ended March31, 2024.On May 2, 2024, the Board of Directors declared a $0.11 per share cash dividend payable on May 31, 2024 to shareholders of record on May 17, 2024. The Company has paid $141.2 million in cash dividends since May 2023. First quarter net income was $11.1 million, or $0.30 per basic share. Adjusted net income was $8.4 million, or $0.23 per basic share. Adjusted EBITDA of $14.7 million for the three-month period ended March 31, 2024. During the first quarter of 2024, lease operating expense  was $10.9 million or $7.92 per Boe. The Company continues to focus on its operating costs and safely maximizing the value of its asset base through prudent expenditure programs, cost management efforts, and continuous pursuit of initiatives that safely drive cost efficiency in the field. The Company successfully managed the operationa","market":"us","thumbnail":"https://s.yimg.com/uu/api/res/1.2/tpzql.1rGDqQ2Xwnd_Uwxg--~B/aD0xNDQ7dz00MDA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/prnewswire.com/ecfed199746f44ea74a177195a997bb2","type":0,"news_type":0,"thumbnails":["https://s.yimg.com/uu/api/res/1.2/tpzql.1rGDqQ2Xwnd_Uwxg--~B/aD0xNDQ7dz00MDA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/prnewswire.com/ecfed199746f44ea74a177195a997bb2"],"rights":{"source":"yahoofinance","url":"https://finance.yahoo.com/news/sandridge-energy-inc-announces-financial-201600281.html","rn_cache_url":null,"customStyle":"img, svg { display: none !important; }","selectors":"article","filters":"","directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/sandridge-energy-inc-announces-financial-201600281.html","is_publish_highlight":false,"gpt_icon":0},{"id":"2433238325","title":"Celldex Reports First Quarter 2024 Financial Results and Provides Corporate Update","url":"https://stock-news.laohu8.com/highlight/detail?id=2433238325","media":"GlobeNewswire","top":-1,"share":"https://ttm.financial/m/news/2433238325?lang=en_us&edition=fundamental","pubTime":"2024-05-07 04:01","pubTimestamp":1715025660,"startTime":"0","endTime":"0","summary":"- Phase 3 CSU studies expected to initiate in summer 2024 -- Positive Phase 2 CSU 12 week data reported in late breaking oral presentation at AAAAI 2024; 52 week data to be reported in 2H 2024 -- Enrollment completed in Phase 2 CIndU study; 12 week data expected 2H 2024 -- Phase 2 PN study initiated; enrollment progressing in Phase 2 EoE study -- Atopic dermatitis selected as next indication; Phase 2 study to initiate by YE 2024 -. HAMPTON, N.J., May 06, 2024  -- Celldex Therapeutics, Inc.  today reported financial results for the first quarter ended March 31, 2024 and provided a corporate update.Mr. Marucci continued, “As the year progresses, we look forward to building on our leadership in the development of mast cell-targeted therapeutics. Importantly, the Company is well capitalized with more than $820M in cash to support the continued advancement and expansion of the barzolvolimab program and the introduction of our first bispecific for inflammatory diseases later this year.”","market":"us","thumbnail":"https://s.yimg.com/uu/api/res/1.2/93p.vbTX5JaFZLixROfDUA--~B/aD04MDk7dz0zMzc1O2FwcGlkPXl0YWNoeW9u/https://media.zenfs.com/en/globenewswire.com/029600e15d50813f95bb9ea14198f6a4","type":0,"news_type":0,"thumbnails":["https://s.yimg.com/uu/api/res/1.2/93p.vbTX5JaFZLixROfDUA--~B/aD04MDk7dz0zMzc1O2FwcGlkPXl0YWNoeW9u/https://media.zenfs.com/en/globenewswire.com/029600e15d50813f95bb9ea14198f6a4"],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/celldex-reports-first-quarter-2024-200100066.html","is_publish_highlight":false,"gpt_icon":0},{"id":"2433475400","title":"Publication of Results from Pivotal FOCUS Study in Metastatic Uveal Melanoma Patients treated with HEPZATO KIT","url":"https://stock-news.laohu8.com/highlight/detail?id=2433475400","media":"PR Newswire","top":-1,"share":"https://ttm.financial/m/news/2433475400?lang=en_us&edition=fundamental","pubTime":"2024-05-06 21:00","pubTimestamp":1715000400,"startTime":"0","endTime":"0","summary":"Significantly Higher Overall Response Rate vs Meta-analysis of Historical Controls . Other Efficacy Endpoints Include a 73.6% Disease Control Rate with a 7.7% Complete Response Rate. The Food and Drug Administration  approved HEPZATO KIT on August 14, 2023 based on the results from the pivotal FOCUS study. A total of 91 patients with unresectable mUM were treated with HEPZATO KIT at 23 treatment centers in the US and Europe. Preliminary results from the FOCUS study were presented at the American Society of Clinical Oncology Annual Meeting in 2022.\"My team at the Moffitt Cancer Center and I are very excited about the publication of results from the FOCUS study. The study results are consistent with data obtained from previous clinical studies, as well as our own experience with percutaneous hepatic perfusion  with more than 200 treatments performed at Moffitt over the past 15 years,\" said Dr. Jonathan Zage","market":"us","thumbnail":"https://s.yimg.com/uu/api/res/1.2/S6Ppkfb6D8ONKTtozb8hig--~B/aD04NTt3PTQwMDthcHBpZD15dGFjaHlvbg--/https://media.zenfs.com/en/prnewswire.com/7fc9eda6eec7e517115fc8d26b2cc2f5","type":0,"news_type":0,"thumbnails":["https://s.yimg.com/uu/api/res/1.2/S6Ppkfb6D8ONKTtozb8hig--~B/aD04NTt3PTQwMDthcHBpZD15dGFjaHlvbg--/https://media.zenfs.com/en/prnewswire.com/7fc9eda6eec7e517115fc8d26b2cc2f5"],"rights":{"source":"yahoofinance","url":"https://finance.yahoo.com/news/publication-results-pivotal-focus-study-130000214.html","rn_cache_url":null,"customStyle":"img, svg { display: none !important; }","selectors":"article","filters":"","directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/publication-results-pivotal-focus-study-130000214.html","is_publish_highlight":false,"gpt_icon":0},{"id":"2433788914","title":"SANDRIDGE ENERGY, INC. ANNOUNCES FIRST QUARTER 2024 OPERATIONAL AND FINANCIAL RESULTS RELEASE DATE AND CONFERENCE CALL INFORMATION","url":"https://stock-news.laohu8.com/highlight/detail?id=2433788914","media":"PR Newswire","top":-1,"share":"https://ttm.financial/m/news/2433788914?lang=en_us&edition=fundamental","pubTime":"2024-05-06 20:30","pubTimestamp":1714998600,"startTime":"0","endTime":"0","summary":"OKLAHOMA CITY, May 6, 2024 /PRNewswire/ -- SandRidge Energy, Inc.   today announced plans to release first quarter 2024 operational and financial results after the close of trading on Tuesday, May 7, 2024.","market":"us","thumbnail":"https://s.yimg.com/uu/api/res/1.2/tpzql.1rGDqQ2Xwnd_Uwxg--~B/aD0xNDQ7dz00MDA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/prnewswire.com/ecfed199746f44ea74a177195a997bb2","type":0,"news_type":0,"thumbnails":["https://s.yimg.com/uu/api/res/1.2/tpzql.1rGDqQ2Xwnd_Uwxg--~B/aD0xNDQ7dz00MDA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/prnewswire.com/ecfed199746f44ea74a177195a997bb2"],"rights":{"source":"yahoofinance","url":"https://finance.yahoo.com/news/sandridge-energy-inc-announces-first-123000679.html","rn_cache_url":null,"customStyle":"img, svg { display: none !important; }","selectors":"article","filters":"","directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/sandridge-energy-inc-announces-first-123000679.html","is_publish_highlight":false,"gpt_icon":0},{"id":"2433142422","title":"Lyra Therapeutics Reports Topline Results from Phase 3 ENLIGHTEN 1 Trial for LYR-210 in Chronic Rhinosinusitis","url":"https://stock-news.laohu8.com/highlight/detail?id=2433142422","media":"GlobeNewswire","top":-1,"share":"https://ttm.financial/m/news/2433142422?lang=en_us&edition=fundamental","pubTime":"2024-05-06 11:59","pubTimestamp":1714967940,"startTime":"0","endTime":"0","summary":"ENLIGHTEN 1 trial did not meet its primary endpoint Company plans to evaluate full dataset and path forward  WATERTOWN, Mass., May  06, 2024  (GLOBE NEWSWIRE) -- Lyra Therapeutics, Inc. (Nasdaq: LYRA)","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2024/05/06/2875729/0/en/Lyra-Therapeutics-Reports-Topline-Results-from-Phase-3-ENLIGHTEN-1-Trial-for-LYR-210-in-Chronic-Rhinosinusitis.html","is_publish_highlight":false,"gpt_icon":0},{"id":"2433077124","title":"New Data for BioMarin's VOXZOGO® (vosoritide) for Multiple Growth-Related Conditions in Children Presented at Pediatric Endocrine Society (PES) Annual Meeting","url":"https://stock-news.laohu8.com/highlight/detail?id=2433077124","media":"PR Newswire","top":-1,"share":"https://ttm.financial/m/news/2433077124?lang=en_us&edition=fundamental","pubTime":"2024-05-05 04:00","pubTimestamp":1714852800,"startTime":"0","endTime":"0","summary":"Investigator-Sponsored Phase 2 Study Demonstrated Positive Results in Children with Noonan Syndrome, Idiopathic Short Stature and Other Growth-Related Conditions. BioMarin-SponsoredPhase 3 Data Show Notable Mean Annualized Growth Velocity Increases in Children with Achondroplasia Who Started Treatment During Adolescence. SAN RAFAEL, Calif., May 4, 2024 /PRNewswire/ -- BioMarin Pharmaceutical Inc.  announced that positive new data supporting the safety and efficacy of VOXZOGO  in children with achondroplasia, as well as positive data for investigational uses in growth-related conditions, including idiopathic short stature  and Noonan syndrome, were presented at the 2024 Pediatric Endocrine Society  Annual Meeting in Chicago, May 2-5, 2024. Researchers also presented results from additional studies highlighting the medicine's efficacy and impact on health-related quality of life in children with achondroplasia.Table 1. Annualized Growth Velocity  for children who completed 12 months of V","market":"us","thumbnail":"https://s.yimg.com/uu/api/res/1.2/suDPstQoWk4R2Ypy0p1ZLQ--~B/aD01OTt3PTQwMDthcHBpZD15dGFjaHlvbg--/https://media.zenfs.com/en/prnewswire.com/db94610f2d68c7fd655942d2889db5d2","type":0,"news_type":0,"thumbnails":["https://s.yimg.com/uu/api/res/1.2/suDPstQoWk4R2Ypy0p1ZLQ--~B/aD01OTt3PTQwMDthcHBpZD15dGFjaHlvbg--/https://media.zenfs.com/en/prnewswire.com/db94610f2d68c7fd655942d2889db5d2"],"rights":{"source":"yahoofinance","url":"https://finance.yahoo.com/news/data-biomarins-voxzogo-vosoritide-multiple-200000298.html","rn_cache_url":null,"customStyle":"img, svg { display: none !important; }","selectors":"article","filters":"","directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/data-biomarins-voxzogo-vosoritide-multiple-200000298.html","is_publish_highlight":false,"gpt_icon":0},{"id":"2432922736","title":"Forrester Research: Margin Execution Would Drive Outperformance","url":"https://stock-news.laohu8.com/highlight/detail?id=2432922736","media":"seekingalpha","top":-1,"share":"https://ttm.financial/m/news/2432922736?lang=en_us&edition=fundamental","pubTime":"2024-05-03 18:52","pubTimestamp":1714733561,"startTime":"0","endTime":"0","summary":"Well first, we know their reprints business declined, largely for macro-related reasons, although partly from discontinuing a few products. Reprint sales are where B2B tech vendors \"reprint\"  FORR's research in their marketing material, so as you might expect, demand tracks vendor marketing budgets which are in turn tied to broader economic conditions . But this is a small percentage of revenue, so the impact isn't huge. One more material headwind is the macro situation from incremental budget tightening for both end-users and tech vendors, and indeed, management argues this too. On the tech vendor side, you need not look","market":"hk","thumbnail":"https://static.seekingalpha.com/cdn/s3/uploads/getty_images/1406793901/image_1406793901.jpg","type":0,"news_type":0,"thumbnails":["https://static.seekingalpha.com/cdn/s3/uploads/getty_images/1406793901/image_1406793901.jpg"],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://seekingalpha.com/article/4688987-forrester-research-margin-execution-would-drive-outperformance","is_publish_highlight":false,"gpt_icon":0},{"id":"2432191687","title":"EnerCom Announces Mike Wirth, Chairman and Chief Executive Officer of Chevron, as Keynote Speaker at the 29th Annual EnerCom Denver - The Energy Investment Conference","url":"https://stock-news.laohu8.com/highlight/detail?id=2432191687","media":"PR Newswire","top":-1,"share":"https://ttm.financial/m/news/2432191687?lang=en_us&edition=fundamental","pubTime":"2024-05-02 02:08","pubTimestamp":1714586880,"startTime":"0","endTime":"0","summary":"A growing list of companies has confirmed their participation, and additional companies are being added to the lineup daily. Presentation opportunities are available for E&P, Midstream, OFS, and Energy Transition companies. DENVER, May 1, 2024 EnerCom, Inc. is pleased to announce that Mike Wirth, Chairman and Chief Executive Officer of Chevron, will participate in a Fireside Chat as the lunch keynote speaker on Tuesday, August 20, 2024, at EnerCom Denver - The Energy Investment Conference. For the past 29 years, EnerCom Denver has been the largest independent investor conference for the global oil and gas industry and broadening energy industry that is open to all energy companies, investors, and professionals to participate. This year's conference will occur August 18-21, 2024, at The Westin Denver Downtown.Michael K.  Wirth, 63, has been chairman of the board and chief executive officer of Chevron Corporation since 2018.Wirth served as vice chairman of the board in 2017 and as execut","market":"us","thumbnail":"https://s.yimg.com/uu/api/res/1.2/SMEKka_8A26tHSj.i6E9uw--~B/aD0xNjt3PTE2O2FwcGlkPXl0YWNoeW9u/https://media.zenfs.com/en/prnewswire.com/604dc8df1f624b13244875f57bff922f","type":0,"news_type":0,"thumbnails":["https://s.yimg.com/uu/api/res/1.2/SMEKka_8A26tHSj.i6E9uw--~B/aD0xNjt3PTE2O2FwcGlkPXl0YWNoeW9u/https://media.zenfs.com/en/prnewswire.com/604dc8df1f624b13244875f57bff922f"],"rights":{"source":"yahoofinance","url":"https://finance.yahoo.com/news/enercom-announces-mike-wirth-chairman-180800403.html","rn_cache_url":null,"customStyle":"img, svg { display: none !important; }","selectors":"article","filters":"","directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/enercom-announces-mike-wirth-chairman-180800403.html","is_publish_highlight":false,"gpt_icon":0},{"id":"2432666553","title":"Asus won’t say if the ROG Ally’s SD card reader will ever be truly fixed","url":"https://stock-news.laohu8.com/highlight/detail?id=2432666553","media":"The Verge","top":-1,"share":"https://ttm.financial/m/news/2432666553?lang=en_us&edition=fundamental","pubTime":"2024-05-01 23:15","pubTimestamp":1714576502,"startTime":"0","endTime":"0","summary":"When I asked whether there was a fix, and what percentage of ROG Ally systems have this issue, the company completely dodged my questions. Here’s an email conversation I had with Asus rep Anthony Spence:1) HasAsusactually found a hardware fix for the faulty SD card readers?If someone RMAs their Ally toAsusthis way, will they get an SD card reader that no longer fails?Our commitment is to assist all customers effectively. If any user suspects they’re encountering issues with their products, we encourage them to reach out and make use of our RMA process as needed. They can expect us to provide a suitable resolution.2) What percentage of ROG Ally systems havethis issue?We cannot comment on this at this time.3) Assuming there is no hardware fix yet, why has the warranty only been extended by one year?Apologies Sean, but we cannot comment on assumptions.4) What doesAsusplan to do for customers in territories outside the US?Will we see warranty extensions and SD card reimbursement elsewhere?","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://www.theverge.com/2024/5/1/24146755/asus-rog-ally-sd-card-reader","is_publish_highlight":false,"gpt_icon":0},{"id":"2431282004","title":"Rhythm Pharmaceuticals Announces Publication of Results from Phase 2 Study of Setmelanotide for the Treatment of Hypothalamic Obesity in The Lancet Diabetes & Endocrinology","url":"https://stock-news.laohu8.com/highlight/detail?id=2431282004","media":"GlobeNewswire","top":-1,"share":"https://ttm.financial/m/news/2431282004?lang=en_us&edition=fundamental","pubTime":"2024-04-29 22:30","pubTimestamp":1714401000,"startTime":"0","endTime":"0","summary":"- Publication highlights administration of setmelanotide therapy resulted in a mean percent reduction in BMI of 15% at 16 weeks and 26% at one year of treatment - - Topline data from ongoing pivotal P","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2024/04/29/2871725/0/en/Rhythm-Pharmaceuticals-Announces-Publication-of-Results-from-Phase-2-Study-of-Setmelanotide-for-the-Treatment-of-Hypothalamic-Obesity-in-The-Lancet-Diabetes-Endocrinology.html","is_publish_highlight":false,"gpt_icon":0},{"id":"2430196212","title":"SD Entertainment Raises FY Net View to Y117.00M","url":"https://stock-news.laohu8.com/highlight/detail?id=2430196212","media":"Dow Jones","top":-1,"share":"https://ttm.financial/m/news/2430196212?lang=en_us&edition=fundamental","pubTime":"2024-04-26 14:30","pubTimestamp":1714113000,"startTime":"0","endTime":"0","summary":"This content was automatically published based on data and/or text from the original source. For feedback, write to singaporeeditors@dowjones.com.","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"gpt_icon":0},{"id":"2428266919","title":"Chevron: Resilient To Oil Price Volatility But Wait For A Pullback","url":"https://stock-news.laohu8.com/highlight/detail?id=2428266919","media":"seekingalpha","top":-1,"share":"https://ttm.financial/m/news/2428266919?lang=en_us&edition=fundamental","pubTime":"2024-04-20 00:20","pubTimestamp":1713543630,"startTime":"0","endTime":"0","summary":"Chevron is a strong performer in the oil industry with a low valuation, excellent balance sheet, and strong cash flows.The company has a history of shareholder-friendly practices, including growing di","market":"nz","thumbnail":"https://static.seekingalpha.com/cdn/s3/uploads/getty_images/1396177379/image_1396177379.jpg","type":0,"news_type":0,"thumbnails":["https://static.seekingalpha.com/cdn/s3/uploads/getty_images/1396177379/image_1396177379.jpg"],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://seekingalpha.com/article/4684737-chevron-resilient-to-oil-price-volatility-but-wait-for-a-pullback","is_publish_highlight":false,"gpt_icon":0},{"id":"2428620314","title":"Celldex Announces Completion of Enrollment in Phase 2 Study of Barzolvolimab in Patients with Chronic Inducible Urticaria","url":"https://stock-news.laohu8.com/highlight/detail?id=2428620314","media":"GlobeNewswire","top":-1,"share":"https://ttm.financial/m/news/2428620314?lang=en_us&edition=fundamental","pubTime":"2024-04-17 20:01","pubTimestamp":1713355260,"startTime":"0","endTime":"0","summary":"HAMPTON, N.J., April 17, 2024  -- Celldex Therapeutics, Inc.  today announced that patient enrollment has been completed in the Company’s Phase 2 clinical study of barzolvolimab for the treatment of the two most common forms of chronic inducible urticaria —cold urticaria  and symptomatic dermographism . CIndU is characterized by the occurrence of hives or wheals that have an attributable trigger associated with them—temperatures below skin temperature in ColdU and scratching/rubbing of the skin in SD. Mast cell activation is known to be a critical driver in ColdU and SD. Barzolvolimab is a humanized monoclonal antibody that specifically binds the receptor tyrosine kinase KIT with high specificity and potently inhibits its activity, which is required for mast cell function and survival. In February 2024, the Company presented positive 12 week primary endpoint results from its ongoing Phase 2 study of barzolvolimab in the most common form of chronic urticaria—chronic spontaneous urticari","market":"us","thumbnail":"https://s.yimg.com/uu/api/res/1.2/93p.vbTX5JaFZLixROfDUA--~B/aD04MDk7dz0zMzc1O2FwcGlkPXl0YWNoeW9u/https://media.zenfs.com/en/globenewswire.com/029600e15d50813f95bb9ea14198f6a4","type":0,"news_type":0,"thumbnails":["https://s.yimg.com/uu/api/res/1.2/93p.vbTX5JaFZLixROfDUA--~B/aD04MDk7dz0zMzc1O2FwcGlkPXl0YWNoeW9u/https://media.zenfs.com/en/globenewswire.com/029600e15d50813f95bb9ea14198f6a4"],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/celldex-announces-completion-enrollment-phase-120100501.html","is_publish_highlight":false,"gpt_icon":0}],"profile":{"websiteUrl":"http://www.sandridgeenergy.com","stockEarnings":[{"period":"1week","weight":-0.0015},{"period":"1month","weight":-0.0904},{"period":"3month","weight":0.0969},{"period":"6month","weight":-0.0497},{"period":"1year","weight":-0.0416},{"period":"ytd","weight":-0.0066}],"compareEarnings":[{"period":"1week","weight":0.03},{"period":"1month","weight":0.0016},{"period":"3month","weight":0.0378},{"period":"6month","weight":0.1806},{"period":"1year","weight":0.2599},{"period":"ytd","weight":0.0944}],"compareStock":{"symbol":"SPY","name":"SPDR S&P 500 ETF Trust"},"description":"SandRidge Energy, Inc. engages in the acquisition, development, and production of oil and natural gas primarily in the United States Mid-Continent. As of December 31, 2022, it had an interest in 1,471 gross producing wells. The company was incorporated in 2006 and is headquartered in Oklahoma City, Oklahoma.","yearOnYearQuotes":[{"month":1,"riseRate":0.5,"avgChangeRate":-0.016517},{"month":2,"riseRate":0.25,"avgChangeRate":-0.048623},{"month":3,"riseRate":0.5,"avgChangeRate":-0.053699},{"month":4,"riseRate":0.625,"avgChangeRate":0.171896},{"month":5,"riseRate":0.375,"avgChangeRate":0.026435},{"month":6,"riseRate":0.571429,"avgChangeRate":-0.01569},{"month":7,"riseRate":0.571429,"avgChangeRate":0.04181},{"month":8,"riseRate":0.428571,"avgChangeRate":0.045272},{"month":9,"riseRate":0.571429,"avgChangeRate":0.017026},{"month":10,"riseRate":0.428571,"avgChangeRate":-0.01626},{"month":11,"riseRate":0.375,"avgChangeRate":0.020746},{"month":12,"riseRate":0.5,"avgChangeRate":0.024447}],"exchange":"NYSE","name":"Sandridge Energy Inc.","nameEN":"Sandridge Energy Inc."},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"deviceId":"web-server-community-laohu8-v3","version":"4.22.4","shortVersion":"4.22.4","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"Sandridge Energy Inc.(SD),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community","description":"Find the latest Sandridge Energy Inc.(SD) stock quote, history, news, and investing ideas from To The Moon - Tiger Brokers Online Investing Community to stay on top of the markets.","keywords":"Sandridge Energy Inc.,SD,Sandridge Energy Inc.股票,Sandridge Energy Inc.股票老虎,Sandridge Energy Inc.股票老虎国际,Sandridge Energy Inc.行情,Sandridge Energy Inc.股票行情,Sandridge Energy Inc.股价,Sandridge Energy Inc.股市,Sandridge Energy Inc.股票价格,Sandridge Energy Inc.股票交易,Sandridge Energy Inc.股票购买,Sandridge Energy Inc.股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"Sandridge Energy Inc.(SD),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community","og_description":"Find the latest Sandridge Energy Inc.(SD) stock quote, history, news, and investing ideas from To The Moon - Tiger Brokers Online Investing Community to stay on top of the markets.","og_image":"https://community-static.tradeup.com/news/9b6dafd60190235ae8e2c95f52c583a0"}}}

Introduction